Financial Performance - The company generated Q2 2025 net revenue of $37.2 million and year-to-date 2025 net revenue of $76.1 million[9] - Acute Care franchise revenue grew by 55.5% for the three months ended June 30, 2025, compared to the same period last year[9] - The company achieved a record year-to-date 2025 adjusted EBITDA of $7.9 million[9] - Net product sales for Q2 2025 were $37.2 million, compared to $36.024 million in Q2 2024[32] - Adjusted EBITDA for Q2 2025 was $1.771 million, compared to $(1.234) million in Q2 2024[34] Product Performance - ZYNRELEF unit demand grew by 6.3% in Q2 2025 compared to Q1 2025[9] - APONVIE unit demand grew by 19% in Q2 2025 compared to Q1 2025[9] - Acute Care franchise net sales were $10.7 million for the three months ended June 30, 2025[14] - Oncology Care franchise net sales were $26.5 million for the three months ended June 30, 2025[26] Refinancing and Capital Structure - The company completed a comprehensive refinancing of prior debt facilities, reducing total debt from $175 million to $145 million and extending the bullet maturity to 2030+[9] - $110 million was funded at closing from Hercules Capital as a senior secured term loan[38] - $35 million of 50% Senior Convertible Notes were issued to Rubric Capital Management due in 2031[38]

Financial Performance - Revenue for Q2 2025 increased by 896% year-over-year to $3146 million from $1660 million in Q2 2024[52, 55] - Genomics revenue reached $2418 million, a 1153% increase compared to Q2 2024[55] - Data and Services revenue totaled $728 million, growing 357% year-over-year, with Insights (data licensing) growing 407%[55] - Gross profit improved by 1583% year-over-year, reaching $1950 million in Q2 2025[52, 55] - Adjusted EBITDA improved by 821%, with a loss of $(56) million in Q2 2025 compared to $(312) million in Q2 2024[52, 55] Genomics Business - Oncology testing (Tempus Genomics) revenue was $1332 million, up 329% year-over-year, with approximately 26% volume growth[55] - Hereditary testing (Ambry Genetics) contributed $973 million of revenue, up 336% year-over-year on a pro forma basis, with approximately 32% volume growth[55] - Average reimbursement per hereditary test was $760 in Q2 2025[24] Data and AI - Total Remaining Contract Value for Data and Services was >$940 million at the end of 2024[39] - Data Licensing Retention was ~140% at the end of 2024[39] - Tempus has >350 petabytes of rich multimodal healthcare data[12, 37]

Company Overview - China Yuchai International Limited (CYD) holds a 76.4% equity interest in Guangxi Yuchai Machinery Company Limited (GYMCL)[9] - Yuchai has a total engine production capacity of 600,000 units per annum[11] - Yuchai has over 3,000 domestic service stations throughout China[11] Market and Sales - China's GDP is targeted to grow approximately 5% for 2025[20] - In 2024, commercial vehicle industry unit sales reached 1 million, a YoY decrease of 9.9%[20] - In 2024, total truck sales increased by 15% YoY, with the HD segment accounting for 43% of total truck sales[24] - In 2024, total bus sales approximated 300,000 units, an increase of 28% YoY[24] - China Yuchai's total unit sales in 2024 (excluding NEV) were 344,486 units[31] Financial Performance - In 2024, the company's revenue reached RMB 19.1 billion[128] - The gross profit percentage in 2024 was 14.7%[136] - The profit after tax in 2024 was RMB 0.5 billion[136] - As of 2024, the company's cash and bank balance was RMB 6.4 billion[137] - In 2024, a share buyback was conducted for approximately US$ 39.8 million[142]

Financial Performance - The estimated combined risk-based capital (RBC) ratio is between 405% and 425%[9, 32] - The holding company liquid assets are $0.9 billion[9, 31] - The statutory combined total adjusted capital (TAC) is $5.6 billion[9] - The year-to-date normalized statutory loss is $0.1 billion[9] - Adjusted earnings were $198 million, $60 million below expectations, primarily due to a lower alternative investment income yield of 1.5%[9] Segment Performance - Annuities adjusted earnings, less notable items, were $332 million, an increase of 8% compared to 2Q 2024[12, 69] - Life Insurance adjusted earnings, less notable items, were $(26) million[17, 69] - Run-off adjusted earnings (loss), less notable items, were $(83) million[23, 69] - Corporate & Other adjusted earnings (loss), less notable items, were $(25) million[25, 69] Investment Portfolio - Total investments are $127 billion[36] - Fixed maturity securities (FMS) are $87 billion, with 97% investment grade[36] - Commercial mortgage loan portfolio is $12.9 billion, representing 10% of total investments[40]

Company Overview - Docebo's Annual Recurring Revenue (ARR) reached $2331 million as of June 30, 2025[18] - Subscription revenues accounted for 94% of the total revenue for the three months ended June 30, 2025[18] - The company boasts a customer base of 3,978 as of December 31, 2024[18] - Docebo experienced a 36% Subscription Revenue Compound Annual Growth Rate (CAGR) between fiscal year 2020 and fiscal year 2024[19] Market Opportunity - The total addressable market (TAM) for global learning is estimated at ~$30 billion, with customer experience (CX) accounting for 62% (~$185 billion) and employee experience (EX) for 38% (~$115 billion)[25] - The US Federal Government TAM is estimated at $12 billion, while the US SLED (State and Local Government Education) TAM is ~$27 billion[28] Financial Performance - Docebo generated approximately $60 million in cash since 2016 while growing ARR to $2331 million by the end of Q2 2025[103] - In Q2 2025, the subscription revenue growth was 145%[98] - The Adjusted EBITDA margin for Q2 2025 was 152%[102] - The Free Cash Flow margin for Q2 2025 was 187%[102] Customer Success - Brooks Automation reduced training costs by 20% using Docebo[63] - One customer training program saw 600,000+ registered users globally[66] - Another customer saved $15 million in training costs over 3 years[67]

Second Quarter 2025 Earnings Presentation August 8, 2025 Forward Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that these expectati ...

Financial Performance - Q3 FY2025 - Reported revenue reached $295.5 million, an increase of 8.4% compared to the prior year period[13, 15] - Adjusted constant currency revenue growth was 8.0%[13, 15] - GAAP gross profit was $197.1 million with a margin of 66.7%[15] - Adjusted EBITDA was $131.0 million with a margin of 44.3%[15] - GAAP net income per diluted share was $0.78, compared to $0.25 in the prior year period[15] - Adjusted net income per diluted share was $1.12, compared to $0.74 in the prior year period[15] Financial Performance - Nine Months Ended FY2025 - Adjusted revenue was $816.4 million, a decrease of 2.5% compared to the prior year period[28] - Adjusted constant currency revenue decreased by 1.7%[28] FY2025 Updated Financial Guidance - Reported revenue is projected to be between $1.078 billion and $1.085 billion, representing a decline of 4.0% to 3.4%[16] - Adjusted constant currency revenue growth is expected to be between -3.6% and -3.0%[16] - Adjusted earnings per diluted share are projected to be between $2.90 and $2.95[16] - Adjusted EBITDA margin is expected to be between 37.25% and 37.50%[16] Strategic Priorities - The company paid down approximately $52 million of term loan B during the third quarter, reaching approximately $112 million in year-to-date debt reduction[11] - The company expects to generate pre-tax cost savings of between $7 million and $8 million during the second half of FY 2025 from the restructuring plan[11] - The company significantly advanced the U S and Canada brand transition, with substantial completion expected by the end of FY 2025[8, 24]

Financial Highlights - Adjusted operating income was $50 million, or $1.01 per share, for the second quarter of 2025[9] - The company insured $10 billion of new business par in the second quarter of 2025, the largest second-quarter amount in a decade[9] - The company generated $64 million of new business production (PVP) in the second quarter of 2025[9] - Pretax adjusted operating income from asset management was $5 million in the second quarter of 2025[9] - Pretax adjusted operating income from the alternative investment portfolio was $16 million in the second quarter of 2025[9] - Capital returned to shareholders in the second quarter of 2025 was $150 million, including share repurchases of $131 million (1.5 million shares) and dividends of $19 million[9] - Adjusted operating income was $212 million, or $4.21 per share, in the first half of 2025, a 23% increase compared to the first half of 2024[11] - The company insured $15 billion of new business par in the first half of 2025, the largest amount of first-half par insured in a decade[15] - The company generated $103 million of PVP in the first half of 2025[15] - The company repurchased nearly 3 million shares at a total cost of $251 million in the first half of 2025, representing nearly 6% of shares outstanding on December 31, 2024[15]

Acquisition and Refinancing - FTAI Infrastructure is acquiring the Wheeling & Lake Erie Railway (W&LE) for $1.05 billion[13] - The combined Transtar / W&LE business is expected to generate annual Adjusted EBITDA of $200+ million by the end of 2026[16] - Corporate fixed charges are expected to reduce by ~$30 million annually due to refinancing[19] - $2.25 billion of new capital is being issued, including $1.25 billion in new corporate debt and $1.0 billion of preferred stock[21] Q2 2025 Financial Performance - Consolidated Adjusted EBITDA for Q2 2025 was $45.9 million[29] - Transtar's Adjusted EBITDA for Q2 2025 was $20.7 million, up 4% from Q1 2025[25, 31] - Long Ridge's Adjusted EBITDA for Q2 2025 was $23.0 million[25, 32] - Jefferson Terminal's Adjusted EBITDA for Q2 2025 was $11.1 million[25, 34] - Repauno's Adjusted EBITDA for Q2 2025 was $(2.1) million[25, 34] Growth Opportunities - Expect ~$15+ million of incremental annual Adjusted EBITDA from Nippon's investments in U S Steel facilities[37] - Two contracts commencing in fall 2025 at Jefferson Terminal represent $20 million of incremental annual Adjusted EBITDA[34, 45] - Contracts and a LOI in place at Repauno represent approximately $80 million of annual Adjusted EBITDA[34]

Financial Performance - The company reported a GAAP net loss of $2.7 million, or $0.04 per share, in 2Q25 [7] - The adjusted net loss was $1.4 million, or $0.02 per share [7] - Adjusted EBITDA decreased by $0.6 million year-over-year to $15.3 million in 2Q25 [8] Capital Allocation - The company repurchased $1 million in shares of common stock at an average price of $4.96 per share during 2Q25 [9] - The company announced the sale of the Handysized Strategic Endeavor for $7.7 million and the purchase of the remaining 49% equity ownership of Seamar Management for $2.7 million [9] - Financing process began for the Strategic Spirit and Strategic Vision, each for $9 million, expected to close in Q3 2025 [9] Operational Highlights - TCE rates outperformed benchmark Panamax, Supramax and Handysize indices by 17% [6] - As of August 6, 2025, 3,671 days were booked at an average of $14,272/day [9] Vessel Acquisitions - The company purchased 7 vessels for $245 million in 2021 & 2022 [17] - The company purchased 3 vessels for $83 million & Acquired 15 vessels for 1806 million shares in 2023 & 2024 [17]